View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 8, 2021

Horizon begins subject recruitment in thyroid eye disease medicine trial

The trial’s primary efficacy goal is the change from baseline at week 24 in proptosis.

Horizon Therapeutics has enrolled the first subject in the Phase IV clinical trial of Tepezza for the treatment of chronic (inactive) thyroid eye disease (TED).

The first-ever medicine to obtain the US Food and Drug Administration (FDA), Tepezza is intended for treating TED, a critical, progressive and possibly vision-threatening rare autoimmune disease.

TED starts with an acute (active) phase in which inflammatory signs and symptoms, including eye pain; swelling; proptosis or eye bulging; and diplopia or double vision, advances over time.

The randomised, double-masked, placebo-controlled, parallel-group, multicentre trial will assess the efficacy, safety and tolerability of Tepezza versus placebo to treat chronic TED patients.

It will enrol 60 adult subjects aged 18 years and have had a preliminary initial diagnosis of TED for a minimum of three years and under eight years.

The participants will be categorised in a 2:1 ratio to receive an infusion of either Tepezza or a placebo.

At first infusion, subjects will receive 10mg/kg followed by 20mg/kg seven times once every three weeks, totalling eight infusions.

The change from baseline at week 24 in proptosis in the study eye will be the trial’s primary efficacy goal.

The proptosis responder rate, diplopia responder rate, change in orbital pain, muscle volume and in the Graves’ Ophthalmopathy Quality of Life questionnaire appearance and visual functioning subscales, will also be assessed.

Proptosis non-responders, who have concluded the therapy period, can choose to be part of the open-label extension period in which subjects will receive another eight infusions of Tepezza.

Horizon research and development executive vice-president Elizabeth Thompson said: “Thyroid eye disease is complex and changes over time, presenting unique challenges at every stage.

“Tepezza is indicated for thyroid eye disease, which includes both acute and chronic phases, and this trial will expand our understanding of the role it can play in helping people living with chronic disease.”

In June 2021, Horizon and Arrowhead Pharmaceuticals entered a global partnership and licence agreement to develop the former’s ribonucleic acid interference therapeutic, ARO-XDH.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU